Entrepreneur Marc Coucke leaves the board of directors of Mithra, which he chairs. The Liège pharmaceutical company reports this on Tuesday morning.
–
Mithra wants to renew its board of directors. This is necessary to support and accelerate the growth of the biotech company – which now has 350 employees – and the marketing of the contraceptive pill Estelle ‘, it sounds. Mithra wants to have new appointments approved at an extraordinary general meeting.
Seven of the thirteen would leave the current board of directors. Among them chairman Marc Coucke, who, after founder and CEO François Fornieri, owns the largest share of shares (15.13 percent). In a response Coucke looks back with satisfaction on the development of Mithra over the past five years. “I will continue to closely support the evolution of the group as a shareholder,” he says.
In addition to the six remaining members of the board of directors, three new faces will be nominated at the extraordinary general meeting. These are profiles with ‘expertise and competences in the pharmaceutical and financial sector’. Among others, the former chairman of Janssen Pharmaceutica, Ajit Shetty, is brought in and will immediately become chairman of Mithra. Director Patricia van Dijck (GSK) is currently taking on that position ad interim.
The intention is that Jean Stéphenne, former CEO of GSK Biologicals, will also supplement the board of directors by mid-2021. He is currently working on a corona vaccine for the German biotech company CureVac.
– .
